Streetbeat News

Analyst Ratings

CLB

Stifel analyst Stephen Gengaro maintains a Hold rating on Core Laboratories (NYSE:CLB) and raises the price target from $17 to $18.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 3:18 pm

COLM

Stifel analyst Jim Duffy maintains a Hold rating on Columbia Sportswear (NASDAQ:COLM) and raises the price target from $75 to $84.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 3:17 pm

GOOG

MSFT

Dan Ives of Wedbush praised the March 2024 quarter earnings of Microsoft Corp. (MSFT) and Alphabet Inc. (GOOG, GOOGL), highlighting the significant investment in AI technologies as a pivotal moment akin to the 'fourth industrial revolution'. Both companies exceeded analyst expectations, with Microsoft reporting a 17% revenue increase and Alphabet announcing its first-ever dividend after a 15% revenue growth. Ives compared this period to a '1995 moment' for AI, indicating a major industry shift.

Portfolio Pulse from Rounak Jain

April 26, 2024 | 3:17 pm

CHDN

Stifel analyst Jeffrey Stantial maintains a Buy rating on Churchill Downs (CHDN) and raises the price target from $150 to $153.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 3:17 pm

PHAT

Needham analyst Joseph Stringer has reiterated a Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a $26 price target.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 3:16 pm

CHKP

Stifel analyst Adam Borg maintains a Hold rating on Check Point Software (CHKP) and lowers the price target from $170 to $165.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 3:16 pm

CLS

Stifel analyst Matthew Sheerin maintains a Hold rating on Celestica (NYSE:CLS) and raises the price target from $36 to $48.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 3:15 pm

CHKP

Wedbush analyst Daniel Ives reiterates an Outperform rating on Check Point Software (CHKP) and maintains a $185 price target.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 3:14 pm

BYD

Stifel analyst Steven Wieczynski maintains a Hold rating on Boyd Gaming (NYSE:BYD) and lowers the price target from $71 to $65.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 3:13 pm

BPMC

Stifel analyst Bradley Canino has maintained a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and increased the price target from $120 to $130.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 3:13 pm